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Abstract
The DNA sequences are different between the distinct individuals and these 
variations produce the species genetic diversity. SARS-CoV-2 virus is a zoonotic 
SARS-like coronavirus that spreads globally, causing the COVID-19 pandemic dis-
ease. The immune response genes are the most various and different in the human 
genome, correlating with infectious diseases. Genetic variants in the angiotensin-
converting enzyme 2 (ACE2) receptor, TMPRSS2, HO-1, BCL11A, and CYP2D6 are 
predicted to either encourage or inhibit the interaction with the viral proteins and 
subsequently contribute to coronavirus genetic risk factors. The genetic susceptibil-
ity to SARS-CoV-2 was investigated by analyzing different genes’ polymorphisms 
such as ACE2 and TMPRSS2, HO-1, and BCL11A. A specific genetic susceptibility to 
COVID-19 was found through different populations in TMPRSS2, ACE2, HO-1, and 
BCL11A genes. Particularly, ACE2 gene polymorphisms were shown to be correlated 
with pulmonary and cardiovascular conditions by modifying the angiotensinogen-
ACE2 system, which recommends the possible explanations of COVID-19 suscep-
tibility based on genetic diversity. Moreover, the COVID-19 treatment could be 
complicated by such genetic polymorphisms. In conclusion, a good characteriza-
tion of functional polymorphisms and the host genetics can assist in identifying 
the pathophysiology of the disease pathway to stratify the risk evaluation and to 
personalize the treatment procedures.
Keywords: gene polymorphisms, infectious diseases, host genetics, SARS-CoV-2, 
TMPRSS2, HO-1, ACE-2, BCL11A, coronavirus, COVID-19
1. Introduction
Infectious diseases have been and continue to be a source of concern and intimi-
dation for human and animal life, and due to the absence of effective strategies 
in disease control, epidemics appear and spread day after day and cause a signifi-
cant increase in mortality. Over decades, genetic and genomic studies provided 
invulnerable evidence that the host showed a genetic variation in its response to 
infectious agents, that may otherwise affect epidemiological risks, morbidity, and 
Genetic Diversity
2
survival [1–4]. Determining the host genetic implications in the risk of the epi-
demic and its severity remains the biggest obstacle to the infectious disease research 
progression [5, 6]. Because of the large size of the samples required by quantitative 
genetic studies, the definition of disease resistance based on individual mortality 
must be changed because it is easy in any case to know if the subjects’ mortality 
was happening due to the exposition to infectious diseases or not. But, this is not 
true in the case of survival because it is multisided, and it may depend not only on 
an individual’s resistance to infectious agents but also on his ability to survive after 
getting a disease or infection [7, 8].
Obviously, interest has increased in the infectivity genetic regulation, which can 
be described as the capability of a pathogen to infect an individual upon contact. 
Comprehension of the genetic regulation of infectivity is especially relevant if there 
are contrary genomic associations between these traits and elements of tolerance or 
resistance [9–11]. Such unfavorable genetic associations could be arising if sub-
jects with much genetic survival not only come over with infection but also have a 
tendency to shed more pathogens [12]. Endurance and resistance infectivity may be 
controlled by several gene sets with variable contributions, both in degree and direc-
tion for survival [7, 13]. Despite this, no study has investigated these three traits at 
the same time. It is worth noting that plenty of quantitative genetic studies revealed 
variation in genetic resistance [2, 14–16], however, only a few studies showed a 
genetic difference in disease survival [7, 8]. In the context of infectious diseases, 
genomic selection may definitely restrict the spread of the disease by implementing 
a mechanism for determining high-risk people of infection [1].
Almost two decades after the outset of the Severe Acute Respiratory Syndrome 
(SARS), produced by a beta coronavirus, recently called SARS-CoV-1, the world 
was surprised by the emergence of a more virulent and infectious new virus in late 
2019. This virus soon spread to almost all parts of the world and quickly reached 
the epidemic disease state [17]. The new coronavirus 2019 (COVID-19) outbreak 
originated from the SARS-CoV-2 virus suddenly became a major public health 
threat. COVID-19 is characterized by different types of clinical characterizations: 
affected patients can be asymptomatic, symptomatic with mild respiratory symp-
toms, or manifest severe pneumonia [18–21]. It is noted that these estimations are 
variable and began to approach accuracy as more cases are described, examined, 
and analyzed. Curiously enough, there is a clear difference in these estimations 
among different countries, worthy to mention that, the differences in the severity of 
the virus were recorded between the sexes and different age categories [18, 20, 22]. 
The infected cases have increased drastically [23]. Transmission from one person 
to another has been confirmed [24]. The virus was discovered in Bronchoalveolar 
lavage (BAL) [22], saliva and nasopharyngeal swabs [25], sputum [26], and throat 
[27, 28]. Even though the number of patients with COVID-19 was asymptomatic or 
mildly symptomatic still indecisive until now, but some studies have suggested that 
the percentage is between 40 and 80% [29, 30].
Among the most debatable characteristics in the clinical course and patho-
genesis of COVID-19 is the heterogeneous hazard in the development to the acute 
form. Some significant clinical factors have been specified as severe disease predic-
tors in different populations around the world, essentially include old age, male 
sex, obesity, and presence of multiple co-morbidities, such as diabetes mellitus, 
hypertension (HTN), cardiovascular disease, and impaired liver and renal function 
[20, 31–33]. In fact, some patients continue completely without symptoms until 
the final viral shedding, however, others experience a highly aggressive form of the 
disease [34–39]. These severe cases in the clinical picture of COVID-19 firmly pro-
pose that other co-factors may have a vital role in modifying disease development 
and progression. The suppressed immune response in the elders, co-morbidities, 
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or smoking condition, may explain the variances in the COVID-19 disease severity 
between individuals and populations [40], but severe disease has also been detected 
in young persons, apparently free from these risk factors. This shows that most 
risk factors clarifying COVID-19 disease severity are yet mysterious. Therefore, to 
recognize the mechanisms beyond COVID-19 disease severity is critical to provide 
suitable protective measures and sufficient triage approaches, drug innovation 
processes, and eventually the pandemic control. The genetic diversity between 
hosts can be explained the big difference in the incidence of SARS CoV-2 rates and 
the severity of COVID 19.
In this chapter, we will focus on some genetic variants and their implications for 
the severity of COVID-19. From these genes, we will take the consideration of the 
ACE2, TPRSS2, HO-1, and BCL11A genes, and the association between the DNA 
polymorphisms of these genes with the genetic susceptibility of the COVID-19, 
Whereas, systematic investigation of the functional polymorphism in these genes 
among diverse populations could tile the way for reliable medicine and personalized 
treatment approaches for COVID-19, this will call genetics to take the initiative in 
combating the virus pandemic.
2. Pathways of cellular infection by SARS-CoV-2
SARS-CoV-1 and SARS-CoV-2 connect to a similar receptor on the surface 
of human cells, known as angiotensin-converting enzyme 2 (ACE2) [41]. This 
complex particularly includes the receptor-binding domain (RBD) positioned 
within the virus spike protein (S protein). However, recent laboratory studies have 
revealed that unlike SARS-CoV-1, the SARS-CoV-2 RBD favors creating a greater 
binding capacity (i.e. 1204 versus 998 Å) [41, 42]. The SARS-CoV-2 infects and 
enters the infected cell by binding the viral spike protein with ACE2 of the host cell 
through the RBD. Even so, the splitting of spike protein needs to be done by human 
protease, where S protein subunits (S1 and S2) are broken apart from each other, 
with the last domain undergoes considerable structural modifications necessary 
to bind with the cell membrane of the host cell [43]. The transmembrane serine 
Figure 1. 
Illustration of the COVID-19 virus spike protein. Across ACE-2 receptors, the spike invades the cell. Afterward, 
the spike is cleaved by the host cell proteases, membrane protease 2 (TMPRSS2), and furin, which results in 
COVID-19 infection activation [48].
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protease 2 (TMPRSS2), together with lysosomal cathepsins, considers one of the 
most crucial proteases in this approach [44]. Moreover, a type 1 membrane-bound 
enzyme (furin), also splits the site between SARS-CoV-2 spike protein (both S1 
and S2 subunits). Most significantly, furin can be expressed in numerous organs, 
involving the lungs. Furin stimulates the splitting of spike protein (S1/S2) after 
the binding of SARS-CoV-2 to ACE2 receptor, and this stimulation by itself is 
necessary to enter the virus into the cell [45]. This different pathway, which 
includes furin-mediate activation, would allow SARS-CoV-2 to be less dependent 
on co-expressions of TMPRSS2 on the cell surface of the infect cells. Hence, 
SARS-CoV-2 could be able to enter a wide range of low TMPRSS2 expressing cells. 
Lastly, disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) 
stimulate the release of ectodomains for a number of transmembrane proteins, such 
as ACE2 [46]. Therefore, increased ADAM17 activity is thought to be correlated 
with increased shedding of ACE2 and eventually decreases the possibility of cellular 
entry by SARS-CoV-2 [47] (Figure 1).
3. ACE2 expression in human tissues
The expression of ACE2 in the different human tissues was controversial because 
ACE2 was newly identified as a major binding site across which SARS-CoV-2 
enters human host cells. Recently, many studies were performed to detect the cell 
types where ACE2 receptor is mainly expressed, which could describe the possible 
SARS-CoV-2 targets. One study was conducted to address the expression of ACE2 in 
various natural human tissues, and the analysis of the results regarding age and sex. 
Highest ACE2 expression levels were detected in the tissues of the small intestine, 
testicle, thyroid heart, adipose tissues, and kidneys. Esophagus, pancreas, lungs, 
liver, adrenal gland bladder, and colon were found to express the intermediate level 
while the lowest expression was found in the stomach nerves, blood vessels, uterus, 
muscle, spleen, bone marrow, and brain. Regarding lungs, the levels of ACE2 
expression were upregulated and downregulated in relation to the immune pattern 
of men and women respectively [49]. ACE2 also was expressed in certain types of 
epithelial cells in the airway, such as type II alveolar epithelial cells and ciliated nasal 
epithelium. Moreover, it was found to be highly co-expressed with the TMPRSS2 
in the nasal epithelium, which explains their higher infectivity by COVID-19 [50]. 
ACE2 is localizing also on the oral cavity mucosa. For now, these results revealed 
the underlying mechanism that the oral cavity poses a significant potential risk 
for 2019-nCoV susceptibility, and ACE2 was also expressed in lymphocytes inside 
the oral mucosa [51]. These findings have reminded us that COVID-19 attacks the 
lymphocytes and causes lymphopenia, mostly in severe forms of the disease [52].
More importantly, ACE2 also are expressed in endothelial cells [53]. That 
explains why COVID-19 disease affects multiorgan in the patients [54]. these results 
indicate that SARS-CoV-2 virus promotes the initiation of endotheliitis in many 
organs as a direct result of the viral intervention and the inflammatory response 
of the host. Additionally, the triggering of pyroptosis and apoptosis may have an 
important role in endothelial cell injury in COVID-19 patients and can account for 
the weakened systemic microcirculatory performance in various blood vessels and 
their clinical consequences in COVID-19 patients [55]. This supposition affords 
justifications for treatments to stabilize the endothelium during viral reproduc-
tion, especially by anti-inflammatory cytokines drugs, cholesterol-lowering drugs, 
and ACE inhibitors [56–59]. This approach can be especially appropriate for weak 
patients with an earlier endothelial disorder, such as hypertension, diabetes mellitus, 
obesity, cardiovascular disease co-morbidities patients [55].
5Co-Evolution between New Coronavirus (SARS-CoV-2) and Genetic Diversity: Insights…
DOI: http://dx.doi.org/10.5772/intechopen.93676
4. Implication of human polymorphism of ACE2 in disease susceptibility
A lot of ACE2 variants have been recognized in different databases [60, 61]. over 
the last decades, much focus has been assigned on some of ACE2 polymorphisms, 
due to their effects on the development of cardiovascular disease (CVD) and, more 
specifically, their association with hypertension (HT). ACE2 restricts the negative 
profibrotic and vasoconstrictor influences of AngII, as the breakdown of AngII to 
Ang (1-7) decreases the AngII oxidative stress of the cerebral arteries endothelium 
[62]. Ang (1-7) has been stated to have antifibrotic and vasodilation [63, 64]. Low 
cardiac expression of ACE2 levels has been notified in hypertension and diabetes 
heart failure [65, 66]. ACE2 gene polymorphisms were first detected in the Chinese 
people with different ACE2 variants (rs4830542, rs4240157, and rs4646155) linked 
to hypertension (HT) [67–70]. Also, ACE2 SNP rs21068809 (C > T) was found to 
be linked to the clinical features of HT [71]. In India, a study of 246 patients with 
HT and 274 normal subjects showed a connection of ACE2 rs21068809 SNP with 
HT [72]. in Brazilian cohorts, a study of genetic association of the combination of 
ACE2 G8790A and ACE I/D polymorphisms reveal susceptibility to HT [73]. ACE 
polymorphism has been described in African- Americans with HT [74].
5. Viral ACE2 receptor polymorphism and coronavirus infection
ACE2 gene variants are still possible to affect SARS-CoV-2 infectivity. In SARS-
CoV, the function of the S1 domain of the S protein is to mediate the binding of 
ACE2 receptors while the S2 domain is potentially undergoing post binding trans-
conformational modulations which activate the fusion to the cell membrane [75]. 
The viral (RBD) found in S1 has been adjusted to amino acid number 270 to 510 [76]. 
The Leu584Ala point mutation of ACE2 significantly weakened the shedding activity 
of the enzyme and promoted the entrance of SARS-CoV into the host cells [77]. An 
ACE2 soluble form lacks the transmembrane and cytoplasmic domain was stated 
able to prevent SARS-CoV S protein binding to ACE2 [46]. Recombinant SARS-
CoV-2 spike proteins were observed to downregulated ACE2 expression by releasing 
sACE2 and thus enhancing injury of the lung [78]. SARS-CoV and SARSCoV-2 
participate in the identity of 76% of the amino acid residues necessary for binding 
of ACE2 within the SARS-CoV-2 spike S1 domain. A lot of amino acid residues of 
the ten human ACE2 proteins were compared by multiple sequence alignment, a 
100% identity among the ACE2 sequences was observed in four different ACE2 
isoforms. The role of these ACE2 isoforms remains unpredictable in SARS-CoV-2 
infection outcome. According to the work by Cao et al., [61] 32 polymorphisms of 
ACE2, including 7 hotspot variables (Ile486Val, Lys26Arg, Asn638Ser, Asn720Asp, 
Ser692Pro, Ala627Val, and Leu731Ile/Phe) were identified in different peoples, that 
make some individuals could be more or less susceptible to the virus than others.
In a preliminary study, the distribution of the allele frequency for 1700 polymor-
phisms in the ACE2 gene was conducted between various populations of the world. 
What is noteworthy is that 11 common and rare variants were detected linked to the 
high ACE2 expression. It was observed that their expression is irregularly distrib-
uted among different populations groups. This study found that the polymorphism 
of the ACE2 gene (variant 4,646,127) was closely related to the higher expression 
levels of the ACE2 gene in the East Asian population, and this paved the way to 
study this important issue more specifically [61]. These results were confirmed by 
a similar subsequent study by [79], which also evidenced that the allele frequency 
of these variants associated with overexpression of ACE2. Also, different ACE2 
polymorphisms encoded a number of proteins for SARS-CoV-2 spike protein has 
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been studied, and it was found that each variant differs in compatibility with 
RBD sequence. Specifically, although the majority of genetic variants exhibited 
high physical similarity. Specifically, the two ACE2 gene alleles (rs143936283 and 
rs73635825) showed a quite low binding strength for the SARS-CoV-2 spike protein, 
which could mean a lower possibility of viral binding and possible to infection 
resistance [80]. It has been observed that the probability of some natural genetic 
variants of ACE2, particularly those assigned to attach with the SARS-CoV-2 spike 
protein, may be linked with flexible virus-host interaction, thus likely modifying 
severity and pathogenicity. A large analysis of the genome data-set was performed 
and showed that no less than nine human ACE2 variants (E23K, S19P, I21V, N64K, 
K26R, H378R, T27A, T92I, and Q102P) are prospective to increase predisposition 
to viral binding, while 17 other variants of ACE2 (that is, E37K, K31R, H34R, N33I, 
E35K, Y50F, D38V, G326E, N51S, M62V, D355N, K68E, F72V, Y83H, D509Y, G352V, 
and Q388L) were thought to be protected from viral entry, where they demon-
strated a lower binding tendency to SARS-CoV-2 spike protein [81].
In another study, from five separate Italian centers, the authors found that three 
variants of ACE2 can be specified (p. Gly211Arg, lys26Arg, and p. Asn720Asp). It 
was noted that these three polymorphisms were recurrently identified in the Italian 
population rather than the East Asian population. These variants are closely located 
in the SARS-CoV-2 essential sequence of spike protein binding sites and therefore 
viral entry and division expected to be modified (for example, Asn720Asp is located 
on only 4 amino acids of TMPRSS2 cleavage site) [82]. This may tell a partial 
explanation for the high case mortality rate registered in Italy by comparison to 
China. Despite ACE2 practically serve as a receptor for coronavirus SARS entry into 
human host cells, another does not support the correlation between its common 
gene polymorphisms and receptivity or consequence of SARS [83]. It has also been 
observed that some ACE2 variants show differential efficacy in stimulating neutro-
phils, monocytes, natural killer cells (NK), macrophages, and T helper cells, thus 
Figure 2. 
Diagrammatic representation for the renin-angiotensin system (RAS) pathway. As ACE2/Ang 1-7/
Mas-axis and ACE1/Ang-II/ AT1R-axis occur, SARS-CoV-2 inhibition by cleavage of ACE2 by ADAM17 
appears. ADAM17: ADAM metallopeptidase domain 17; ARBs: angiotensin receptor blockers; MRAs: 
mineralocorticoid receptor antagonists [87].
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may probably either enhance or reduce the inflammatory or “cytokine storm” [84], 
in addition to stimulating the processing of Ang II, thereby improving or exacer-
bating vasoconstriction and participating to the improvement or exacerbation of 
topical or systemic tissue infection [85, 86]. (Figure 2).
6. TMPRSS2 polymorphism analysis with COVID-19 disease
TMPRSS2 and ACE2 have been associated with SARS-corona (CoV) disease, 
influenza, and SARS-CoV-2 in facilitating viral entrance into the infected host cell 
TMPRSS2 considers as an androgen-reactive serine protease enzyme that cleaves 
SARS-CoV-2 Spike protein, mediating viral activation and entry [88]. Single-
nucleotide polymorphisms of TMPRSS2 enzyme have been studied in several 
diseases such as in breast cancer, the rs2276205 (A > G) with low-frequency allele 
was correlated with increased patients’ endurance [89]. In prostate cancer, the 
rs12329760 (C > T) of TMPRSS2 has a higher frequency in men with prostate cancer 
in his family, while ERG gene fusion [90, 91] Rs383510 (T > C) and rs2070788 
Figure 3. 
A polymorphism and dysregulation of ACE2, and TMPRSS2 in COVID-19 and a suggested model for active 




(G > A) were correlated with aggressive H7N9, H1N1, and increased lung expression 
of TMPRSS2 [92]. A study by Hou et al., indicated that 4% of nonidentical variants 
of TMPRSS2 are stop-codon mutations, Meanwhile, 59% are harmful mutations in 
TMPRSS2 coding regions [93]. The harmful variants (p.Arg240Cys, p.Val160Met, 
p.Gly181Arg, p.Pro335Leu, p.Gly432Ala, and p.Gly259Ser) in the coding region of 
TMPRSS2, are the same with somatic alterations arising in various types of cancer. 
In the same contest, Hou et al. found that, the p. Asp435Tyr which is a key site for 
catalytic residue binding of TMPRSS2 has unique low-frequency allele, but pre-
dominant SNPs in TMPRSS2 and offer possible descriptions for differential genetic 
infectivity to COVID-19 and for risk influences, such as those with tumor and male 
patients. By using the analysis of single-cell RNA-seq, Schuler et al. revealed that 
the expression of TMPRSS2 was upregulated in ciliated cells and alveolar epithelial 
type 1 cells and increased with humans aging [94]. This observation indicates that 
the developmental TMPRSS2 expression regulation may have a role in the relative 
protection of the children and infants from COVID-19 infection. Yet, it might be of 
great importance to investigate the link between TMPRSS2 polymorphisms and the 
age relationship with COVID-19 susceptibility (Figure 3).
7.  Heme oxygenase-1 enzyme (HO-1) genetic polymorphisms and 
COVID-19 severity
Many studies demonstrated that the HO-1 gene polymorphisms, particularly the 
promoter region GT dinucleotide repeat mutation regulates the inducibility of HO-1 
to ROS [95–101]. Subjects with more GT repeats have been believed to be more 
sensitive to cardiovascular endothelium diseases such as atherosclerosis coronary 
artery disease and aortic aneurysm s [95, 98, 99]. The lower Expression level of 
HO-1 in those with more GT repeats make the patients to be more affected to 
decrease endothelial hemostasis and inflammation [95–101]. While, GT sequences 
short alleles are correlated with increased HO-1 inducibility, which in turn reduced 
inflammation and enhanced cytoprotection [101]. Patients with COVID-19 compli-
cations perhaps have longer GT sequences and decreased vessel hemostasis.
COVID-19 disease has poor effects in diabetic and obese individuals, maybe 
because those people are already having high interleukin 6 levels of (IL-6) and they 
are in a proinflammatory state due to leptin and insulin resistance [102, 103]. As a 
result, the negative clinical outcomes of COVID-19 infection in obese patients was 
recorded [103]. Peterson et al. have revealed that obesity raises high-density lipopro-
tein (HDL) oxidation [104]. Oxidized HDL (Ox-HDL) is thought to produce pro-
inflammatory cytokines by the direct action on adipocyte stem cells [105]. Ox-HDL 
initiates an inflammatory cascading with inflammatory cytokines, tumor necrosis 
factor (TNF), interleukins (IL-6, IL-1), and increasing of Angiotensin II (ANG II), 
a biomarker for early cardiovascular system disorders [104]. This made the obese 
individuals are more sensitive to heart failure due to infection of COVID-19 [106]. 
Up-regulation of HO-1-derived bilirubin may enhance the COVID-19 bad effect, 
this risk was reduced by an increased HO-1 level [107, 108]. Hence, up-regulation of 
the level of HO-1 with pharmacological treatment [109] may have valuable action in 
acute inflammation conditions.
8. BCL11A polymorphisms
BCL11A Genetic polymorphisms were correlating to produce fetal hemoglobin 
in overall population, and these genetic variants were later found to be able to 
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modify the severity of β-thalassemia and sickle cell diseases. Although the elevation 
of fetal hemoglobin can ameliorate the severity of these disorders. In an attempt 
to best comprehend the genetic background of this heterogeneity, genome-wide 
surveys were performed with 362,129 joint SNPs on a large cohort population of 
β-thalassemia and sickle cell patients to explore the genetic linking and relationship 
with HbF levels, in addition to other traits related to red blood cells. Among the 
principal variants influencing HbF levels, BCL11A SNP rs11886868 in the was com-
pletely correlated with this trait. This BCL11A variant was correlated with raised 
fetal hemoglobin (HbF) production in beta-thalassemia patients. Also, the similar 
BCL11A variants were substantially correlated with sickle cell patients HbF levels. 
These findings show that modifying HbF levels by BCL11A variants, consider as an 
essential factor in improving the beta-thalassemia phenotype and may potentially 
help improve other hemoglobin disorders. These findings can help describe the 
molecular mechanisms for regulating fetal globin and may ultimately participate 
in the evolution of new therapeutic strategies for sickle cell anemia and beta-
thalassemia [110–112]. Hence, these results can provide an explanation of why some 
individuals naturally exhibit diseases mild symptoms, while others have shown very 
acute clinical symptoms. Therefore, it is imperative to perceive the role of genetic 
polymorphisms of these genes in SARS-CoV-2 infection in human populations to 
interpret the observed heterogeneity in predisposition and COVID-19 infection 
severity [88, 113].
9. Genetic polymorphism and therapy effectiveness
COVID-19 may be inactivated or partially treated by the following approaches: 
ACE2 receptor attaching site blocking either by antibody or specific ligand or 
using ACE2 soluble form that can neutralize the virus by binding the virus spike 
protein, and, yet, cover ACE2 binding site on the host cell surface and reducing 
the tissue injury. The genetic polymorphisms of cytochrome (CYP) 2D6 can affect 
drug metabolism using this approach, which contains 50% currently using drugs 
[114]. The metabolism of these genes can be increased by these polymorphisms and 
in turn, reduce their efficiency or significantly decline their metabolism causing 
drug toxicity [115]. Slow drug metabolizers permit toxic effects of the medications 
as chloroquine to become accumulated and resulting in cardiac problems with an 
increased hazard of cardiac arrest, specifically in diabetes and obesity patients. 
CYP2D6 Polymorphism is much high in Asians and African Americans [116–118], 
which extremely influenced by this disorder. One Korea study studying Lupus 
disease demonstrated considerable variation in the level of hydroxychloroquine 
due to polymorphisms of CYP2D6 [119]. This may explain the clinical outcomes 
differences when using this drug. Because of the metabolism abnormalities due to 
these genetic polymorphisms, resistant malaria strains will be arising [120–122]. 
Heart failure patients can be affected by the same CYP 2D6 gene polymorphisms 
since it is accountable for metoprolol metabolism [123, 124]. These gene variants 
affect several other medications such as barbiturates, Isoniazid (INH), serotonin 
reuptake inhibitor (omeprazole hydralazine sulfasalazine, etc.) [125]. Individuals 
with CYP2D6 polymorphisms and the HO-1 GT allele make therapy and disease 
outcomes challenging. Some of the patients who carry these polymorphisms will 
respond perfectly to drugs and have a low risk of COVID-19 patients to develop 
complications such as multiorgan failure and ARDS, while other patients will 
express drug toxicity levels and multiorgan problems [115]. This can describe why 
clinicians are unable to predict the multiorgan failure with COVID −19 disease and 
different outcomes from using 4-aminoquinolones.
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10. Personalized medicine guided by host genetic of COVID-19
SARS-CoV-2 inhibition can be done by spike protein and ACE2 differential 
glycosylation [126]. Several polymorphisms, such as p.Pro389His, p.Met383Thr 
and p.Asp427Tyr slightly inhibited by hydroxychloroquine. This can be clarifying 
why hydroxychloroquine treatment was not significantly in a different hospital 
than others. [127]. However, more pharmacogenomics experiments between the 
genetic data and drug response from COVID-19 patients are extremely needed. The 
viral entry to the host cell by binding to the cell membrane through S protein can 
be blocked by TMPRSS2 [88]. The SARS-CoV-2 pathogenesis and infection depend 
on the TMPRSS2 presence, in a high pH environment [128, 129]. The inhibitor of 
endosomal acidification such as hydroxychloroquine and CatB/L inhibitors might 
work only in absence of TMPRSS2- in SARS-CoV-2 infected and may not work 
or has no or less effective in patients with TMPRSS2 wild-type [128]. So far, the 
populations with missense polymorphisms and stop-gained of TMPRSS2 polymor-
phisms may be good sensitive to treatment with hydroxychloroquine. Furthermore, 
the patients who carry TMPRSS2 and ACE2 wildtype, a mix of hydroxychloroquine 
or chloroquine with camostat may have the best clinical advantage. The ACE2 can 
be cleaved by TMPRSS2 at Arginine 697 to 716 [130], which improves viral entry. 
Thus, patients with, p.Arg710Cys p.Arg708Trp, p.Arg716Cys and p.Arg710His 
polymorphisms in ACE2 might have fewer symptoms of COVID-19 disease as the 
cleavage site of ACE2 gene loses by these polymorphisms (Figure 3) [113].
11. Conclusion
The pandemic COVID-19 by SARS-CoV-2 coronavirus is multifactorial in 
which human inheritances might play a pivotal role together with the co-morbidity 
diseases and other risk factors. The disease clinical course has been depending 
on the link between genetic variants, such as the CYP2D6 enzyme system, HO-1 
(anti-inflammatory gene), and ACE-2 enzyme. Beside ACE2 polymorphisms, there 
is TMPRSS2 gene variance that possibly changes the pathogenicity of the virus by 
changing the interaction between ACE2 and SARS-CoV-2 virus. A good character-
ization of functional polymorphisms and the host genetics can assist in identifying 
the pathophysiology of the disease pathway to stratify the risk evaluation and to 
personalize the treatment procedures.
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